European Commission has approved Eli Lilly and Company's new indication for FORSTEO for the treatment of osteoporosis associated with sustained, systemic glucocorticoid therapy in women and men at increased risk for fracture.
Ads by Google
FDA approved Rotarix, the second oral U.S. licensed vaccine for the prevention of rotavirus, an infection that causes gastroenteritis in infants and children.
Decision Resources forecasts that the Chinese gastric cancer drug market will nearly triple between 2007 and 2012. According to the new Emerging Markets report entitled Gastric Cancer in China, this growth will be fueled by increased access to health insurance and greater patient spending power, leading to increased usage of targeted therapies.
One in six Americans who have ever taken a prescription drug experienced a side effect serious enough to send them to the doctor or hospital, but the majority of consumers don't know they can report these side effects to the FDA, which is responsible for tracking drug safety problems.
A new electronic system for the prescribing of medications will provide Medicaid physicians in Louisiana access to cutting-edge technology to provide safe an efficient prescribing services as well as help drive down medication costs.
FDA has identified 25 drugs and biologic products that will be required to submit safety plans called REMS.
FDA has approved label revisions for Schering-Plough's PEGINTRON and REBETOL combination therapy for chronic hepatitis C, recommending weight-based dosing of REBETOL based on patient body weight.
With a renewed national spotlight on prescription drug abuse, especially among teenagers, it is important to note as well the often over-looked issue of crimes against pharmacies. Despite the fact that robbing a pharmacy to obtain powerful pain killers and other controlled substances is a federal offense punishable by up to 20 years in prison, there are indications that all types of crimes in our nation's community pharmacies -- robberies, burglaries, fraud and other types of diversion -- are on the rise.
A new survey of employers that finds the utilization of pharmacy benefit management tools has helped to slow the cost of prescription drug benefits highlights the value of proven pharmacy benefit manager tools in increasing savings and access for payors and consumers.
FDA approved a new medical adhesive called Artiss for use in attaching skin grafts onto burn patients.
More than 90% of drugs entering clinical development fail to get to market, due to the lack of effectiveness or adverse side effects not detected in animal tests. These false positives could be avoided with pre-clinical tests using stem cell technologies, potentially saving drug developers millions, according to Kalorama Information's new report Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
Sagent Pharmaceuticals has launched ciprofloxacin injection, USP, 5% dextrose premix bag, a synthetic broad spectrum antimicrobial agent for intravenous administration used to treat bacterial infections.
Genetic differences at the site of the beta-2 adrenergic receptor gene in asthma patients did not lead to different responses to Advair Diskus or Serevent Diskus.
Prescription costs rise more than 6 times when patients reach 65 says study of 5M people. Women are 23 percent more likely than men to be prescribed medications.
Approximately 22,000 lives could have been saved had the drug Trasylol been removed from the market. Trasylol was finally taken off the market in November of 2007. The drug, which is used to decrease bleeding during open heart surgery but caused kidney failure which lead to the need for dialysis and an increased change of death for the patients.
Researchers have demonstrated the precision required to engineer a nanoparticle that is effective in targeted drug delivery.
A proposal was discussed that would give FDA the authority to regulate generic versions of biotechnology drugs.
FDA will not submit to Congress a legislative proposal to seek authority to approve generic versions of biotechnology medications.
FDA will seek authority from Congress to approve generic versions of biotechnology drugs.